Corlux Second Phase III Trial Enrolled For Psychotic Major Depression
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Data from three Phase III trials of Corcept's Corlux for psychotic major depression will be available by year-end, the firm said
You may also be interested in...
Corcept Beginning Mifepristone Pivotal Trials For Psychotic Depression
Corcept will begin the first of two pivotal Phase III trials for Corlux (mifepristone) for treatment of psychotic features of psychotic major depression "immediately," the firm said.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product